The influence of infliximab and adalimumab on the expression of apoptosis-related proteins in lamina propria mononuclear cells and enterocytes in Crohn's disease - An immunohistochemical study

Journal of Crohn's and Colitis

Volumn 7, Issue 9, 2013, Pages 706-716

  Eder, Piotr ^a   Lykowska Szuber, Liliana ^a   Krela Kazmierczak, Iwona ^a   Stawczyk Eder, Kamila ^a   Zabel, Maciej ^a   Linke, Krzysztof ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Adalimumab; Apoptosis; Crohn's disease; Deep remission; Infliximab

Indexed keywords

ADALIMUMAB; CASPASE 3; CD4 ANTIGEN; CD8 ANTIGEN; FAS ANTIGEN; INFLIXIMAB; PROTEIN BAX; PROTEIN BCL 2; TUMOR NECROSIS FACTOR RECEPTOR 1;

ADULT; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CROHN DISEASE; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INTESTINE CELL; LAMINA PROPRIA; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; REMISSION;

ADA; ADALIMUMAB; APOPTOSIS; CD; CROHN'S DISEASE; DEEP REMISSION; IFX; INFLIXIMAB; LAMINA PROPRIA MONONUCLEAR CELLS; LPMC; TNF; TUMOR NECROSIS FACTOR;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD4; ANTIGENS, CD8; ANTIGENS, CD95; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CASPASE 3; CELL COUNT; CROHN DISEASE; ENTEROCYTES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INDUCTION CHEMOTHERAPY; INTESTINAL MUCOSA; LEUKOCYTES, MONONUCLEAR; MALE; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; YOUNG ADULT;

EID: 84881554609     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2012.09.006     Document Type: Article

References (40)

1. Pereira W.O., Amarante-Mendes G.P. Apoptosis: a programmed of cell death or cell disposal?. Scand J Immunol 2011, 73:401-407.
2. Fas S.C., Fritzsching B., Suri-Payer E., Krammer P.H. Death receptor signaling and its function in the immune system. Curr Dir Autoimmun 2006, 9:1-17.
3. Strasser A., Jost P.J., Nagata S. The many roles of Fas receptor signaling in the immune system. Immunity 2009, 30:180-192.
4. Gupta S. A decision between life and death during TNF-alpha-induced signaling. J Clin Immunol 2002, 22:185-194.
5. Lindsay J., Esposti M.D., Gilmore A.P. Bcl-2 proteins and mitochondria - specificity in membrane targeting for death. Biochim Biophys Acta 2011, 1813:532-539.
6. Fan T.J., Han L.H., Cong R.S., Liang J. Caspase family proteases and apoptosis. Biochim Biophys Acta 2005, 37:719-727.
7. Stober W., Fuss I.J., Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest 2007, 117:514-521.
8. Neurath M.F., Finotto S., Fuss I.J., Boirivant M., Galle P.R., Strober W. Regulation of T-cell apoptosis in inflammatory bowel disease: to die or not to die, that is the mucosal question. Trends Immunol 2001, 22:21-26.
9. Peppelenbosch M.P., van Deventer S.J. T cell apoptosis and inflammatory bowel disease. Gut 2004, 53:1556-1558.
10. Itoh J., de la Motte C., Strong S.A., Levine A.D., Fiocchi C. Decreased Bax expression by mucosal T cells favours resistance to apoptosis in Crohn's disease. Gut 2001, 49:35-41.
11. Ina K., Itoh J., Fukushima K., Yamaguchi T., Kyokane K., Imada A., et al. Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with Bcl-2/Bax mucosal imbalance. J Immunol 1999, 163:1081-1090.
12. Di Sabatino A., Ciccocioppo R., Luinetti O., Ricevuti L., Morera R., Cifone M.G., et al. Increased enterocyte apoptosis in inflamed areas of Crohn's disease. Dis Colon Rectum 2003, 46:1498-1507.
13. Von Lampe B., Barthel B., Coupland S.E., Riecken E.O., Rosewicz S. Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease. Gut 2000, 47:63-73.
14. Piguet P.F., Vesin C., Guo J., Donati Y., Barazzone C. TNF-induced enterocyte apoptosis in mice is mediated by the TNF receptor 1 and does not require p53. Eur J Immunol 1998, 28:3499-3505.
15. Begue B., Wajant H., Bambou J.C., Dubuquoy L., Siegmund D.D., Beaulieu J.F., et al. Implication of TNF-related apoptosis-inducing ligand in inflammatory intestinal epithelial lesions. Gastroenterology 2006, 130:1962-1974.
16. Rutgeerts P., Vermeire S., van Assche G. Biological therapies for inflammatory bowel diseases. Gastroenterology 2009, 136:1182-1197.
17. Baert F.J., D'Haens G., Peeters M., Hiele M.I., Schaible T.F., Shealy D., et al. Tumor necrosis factor α antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 1999, 116:22-28.
18. Tracey D., Klareskog L., Sasso E.H., Salfeld J.G., Tak P.P. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008, 117:244-279.
19. Lugering A., Schmidt M., Lugering N., Pauels H.G., Domschke W., Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001, 121:1145-1157.
20. Ten Hove T., van Montfrans C., Peppelenbosch M.P., van Deventer S.J. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002, 50:206-211.
21. Van den Brande J.M., Braat H., van den Brink G.R., Versteeg H.H., Hoedmaeker I., van Montfrans C., et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003, 124:1774-1785.
22. Di Sabatino A., Ciccocioppo R., Cinque B., Millimaggi D., Morera R., Ricevuti L., et al. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease. Gut 2004, 53:70-77.
23. Lugering A., Lebiedz P., Koch S., Kucharzik T. Apoptosis as a therapeutic tool in IBD?. Ann N Y Acad Sci 2006, 1072:62-77.
24. Zeissig S., Bojarski C., Buergel N., Mankertz J., Zeitz M., Fromm M., et al. Downregulation of epithelial apoptosis and barrier repair in active Crohn's disease by tumor necrosis factor α antibody treatment. Gut 2004, 53:1295-1302.
25. Nesbitt A., Fossati G., Bergin M., Stephens P., Stephens S., Foulkes R., et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis 2007, 13:1323-1332.
26. Atreya R., Zimmer M., Bartsch B., Waldner M.J., Atreya I., Neumann H., et al. Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF Receptor 2 and intestinal CD14+ macrophages. Gastroenterology 2011, 141:2026-2038.
27. Shen C.C., van Assche G., Rutgeerts P., Ceuppens J.L. Caspase activation and apoptosis induction by adalimumab: demonstration in vitro and in vivo in a chimeric mouse model. Inflamm Bowel Dis 2006, 12:22-28.
28. Shen C., van Assche G., Colpaert S., Maerten P., Geboes K., Rutgeerts P., et al. Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther 2005, 21:251-258.
29. Best W.R., Becktel J.M., Singelton J.W., Kern F. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976, 70:439-444.
30. Daperno M., D'Haens G., van Assche G., Baert F., Bulois P., Maunoury V., et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc 2004, 60:505-512.
31. D'Haens G., Geboes K., Peeters M., Baert F., Penninckx F., Rutgeerts P. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1998, 114:262-267.
32. Hsu S.M., Raine L., Fanger H. Use of avidin-biotin peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981, 29:577-580.
33. Remmele W., Stegner H.E. Vorschlag zur einheitlichen Definition eines immunreaktiven Score (IRS) fur den Immunohistochemichen Ostrogenrezeptor-Nachweis (ER-ICA) im Mammikarzinomgewebe. Patologie 1987, 8:138-140.
34. Ruschoff J., Dietel M., Baretton G., Arbogast S., Walch A., Monges G., et al. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch 2010, 457:299-307.
35. Schmidt M., Lugering N., Lugering A., Pauels H.G., Schulze-Osthoff K., Domschke W., et al. The role of the CD95/CD95L system in glucocorticoid-induced monocyte apoptosis. J Immunol 2001, 166:1344-1351.
36. Mitoma H., Horiuchi T., Hatta N., Tsukamoto H., Harashima S., Kikuchi Y., et al. Infliximab induces potent anti inflammatory responses by outside-to-inside signals through transmembrane TNF-α. Gastroenterology 2005, 128:376-392.
37. Ito H. IL-6 and Crohn's disease. Curr Drug Targets Inflamm Allergy 2003, 2:125-130.
38. Fries W., Muja C., Crisafulli C., Costantino G., Longo G., Cuzzocrea S., et al. Infliximab and etanercept are equally effective in reducing enterocyte apoptosis in experimental colitis. Int J Med Sci 2008, 5:169-180.
39. Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol 2007, 35:495-516.
40. Edelblum K.L., Yan F., Yamaoka T., Polk D.B. Regulation of apoptosis during homeostasis and disease in the intestinal epithelium. Inflamm Bowel Dis 2006, 12:413-424.